Here, our approaches integrating a genetically engineered mouse model, RNA-Seq, and ATAC-Seq have established an epigenetic tumor suppressor model of SETD2 that lays the foundation for developing mechanism-based therapeutic strategies for SETD2-deficient cancers. This evidence concerns the gene SETD2 and neoplasm.